News & Updates
Filter by Specialty:

Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response
A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.
Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response
14 Oct 2021
Smoking reduces effect of methotrexate-based treatment in RA patients
Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.
Smoking reduces effect of methotrexate-based treatment in RA patients
14 Oct 2021
Common, cheap osteoporosis drug promising for T2D
The osteoporosis drug alendronate halves the risk of developing type 2 diabetes (T2D) in a nationwide, retrospective, case-control study of nearly 700,000 patients from Denmark.
Common, cheap osteoporosis drug promising for T2D
14 Oct 2021
Superficial needling acupuncture no better than sham procedure for knee osteoarthritis
Superficial needling acupuncture for 4 weeks does not appear to be more effective than nonpenetration sham acupuncture for knee osteoarthritis (OA), a study has found.
Superficial needling acupuncture no better than sham procedure for knee osteoarthritis
12 Oct 2021
POETYK trials highlight potential of novel drug for plaque psoriasis
The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.
POETYK trials highlight potential of novel drug for plaque psoriasis
11 Oct 2021
Study identifies risk factors for impaired BNT162b2 mRNA antibody response in lupus
Among systemic lupus erythematosus patients, SARS-CoV-2-specific immune responses after BNT162b2 vaccination seem to be impaired in the presence of poor baseline humoral immune status, low naïve B cell frequencies, and mycophenolate mofetil (MMF) and methotrexate (MTX) use, according to a study.
Study identifies risk factors for impaired BNT162b2 mRNA antibody response in lupus
11 Oct 2021
Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA
The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.
Long-term KEEPsAKE data show sustained improvements with risankizumab for PsA
08 Oct 2021
Systemic diseases, smoking history linked to more severe dry eye signs
Certain systemic diseases, such as Sjögren syndrome (SS), facial rosacea, rheumatoid arthritis (RA), and peripheral artery disease, and a history of daily cigarette smoking are significantly associated with more severe dry eye disease (DED) signs, a study has found.
Systemic diseases, smoking history linked to more severe dry eye signs
07 Oct 2021
Retinal thinning may foreshadow neurodegeneration in SLE
Patients with systemic lupus erythematosus (SLE) show progressive reduction in the thickness of peripapillary retinal nerve fibre layer, suggestive of early neurodegeneration, a recent study has found.